Prosecution Insights
Last updated: November 12, 2026
Application No. 18/849,691

BLACK PEPPER CANNABINOID EXTRACT COMPRISING BETA-CARYOPHYLLENE

Non-Final OA §103§112
Filed
Sep 23, 2024
Priority
Apr 04, 2022 — AU 2022900879 +1 more
Examiner
AFREMOVA, VERA
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Natural Innovations Group Pty Ltd.
OA Round
1 (Non-Final)
51%
Grant Probability
Moderate
1-2
OA Rounds
80%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
449 granted / 888 resolved
-9.4% vs TC avg
Strong +29% interview lift
Without
With
+29.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
48 currently pending
Career history
959
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 1-9 and 11-21 as filed on 3/28/2025 are currently pending. Applicant’s election without traverse of the Group I, claims 1-9, in the reply filed on 9/21/2026 is acknowledged. Claims 11-21 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/21/2026. Claims 1-9 as filed on 3/28/2025 are under examination in the instant office action. Claim Rejections - 35 USC § 112 Claims 3 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 is rendered indefinite by the phrase “steep of extracting black pepper is comprised of extracting hydrocarbon”. It is unclear as written whether “hydrocarbon” is an extracting solvent, or whether hydrocarbon is a product of extracting step (terpene oil). Specification par. 0025 discloses “hydrocarbon” as an extraction solvent that would include ethanol and ethyl acetate. However, ethanol and ethyl acetate are not hydrocarbons. Claim 3 is also unclear in the light of specification. Claim 6 recites the limitation "supercritical fluid" derived from black pepper that is extracted with supercritical carbon dioxide. There is insufficient antecedent basis for this limitation in the claim 1. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-5 and 7-9 are rejected under 35 U.S.C. 103 as being unpatentable over US 2020/0199055 (Jansen et al) in view of Geddo et al (Nutrients, 2019, 11, article 2788, pages 1-14). The cited document US 2020/0199055 (Jansen et al) discloses a method for producing a plant cannabinoid extract comprising beta-caryophyllene (BCP) and five or more other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene and linalool (entire document including abstract, par. 0007 and table 5 on page 53). The cited method comprises steps of: Step of extracting plant material to produce a first extract comprising fat-soluble components (fig. 1C, par. 0128-0130; par.0092; par. 0152) Steps of refining including “winterizing” (par. 186, item 445; par. 0201, par. 0246) the first extract with fat-soluble components to remove undesired components (fatty acids, gums, waxes) differentiated by solidification temperature; wherein winterizing comprises chilling the extract at temperature 4°C to 15°C and precipitating undesired components (see par. 0201); wherein low temperature provides for better selection of target extractives such as cannabinoids and terpenes while minimizing extraction of gums, waxes, chlorophylls (par. 0246); wherein the additional undesired components are further removed by filtering the winterized extract through activated carbon (par. 0246, lines 14-17); Step of fractionally distilling the winterized fat-soluble components of the first extract to produce a plurality of plant derived lipid fractions including terpenes, caryophyllene, and cannabinoids (see par. 0259), wherein distillation temperature is 100°C or less (par. 0259, line 8) and distillation pressure is low or below atmospheric such as 10-450 torr (par. 0259, lines 11-14)l and; Step of blending two or more of the lipid fractions to produce final plant cannabinoid extract by adding terpenes collected separately at distillation to the oil fraction with cannabinoids (par. 0281). Thus, the cited method comprises the same major steps of as encompassed by claim 1 (extraction, winterization, fractionation by distillation and blending), wherein the steps are practiced at the same conditions as encompassed by claims 3-5 and 7-9. The final product made by the cited method comprises the same target components including beta-caryophyllene (BCP) and five or more other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene and linalool (table 5 on page 53). But the cited plant cannabinoid extract is made from cannabis plant and not from black pepper as recited in the pending claims; and the cited extract contains less of BCP then recited in claim 1. However, it is known that black pepper plant contains the same target components including beta-caryophyllene (BCP) and five or more other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene, linalool and sabinene; and that extract from black pepper provides for high content of BCP such as 87%; for example: see abstract and table 1, page 6, of the cited reference by Geddo. Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was filed to substitute a black pepper plant material for cannabis plant material in the method of US 2020/0199055 (Jansen et al) for producing a plant cannabinoid extract with beta-caryophyllene (BCP) and other terpenes with a reasonable expectation of success in providing a plant extract with the same target components including high contents of beta-caryophyllene (BCP) and other terpenes including α-pinene, ß-pinene, 3-carene, humulene, limonene, etc because black pepper plant is known to contain the same extractive terpenes and as well as a high amount of BCP as evidenced by Geddo. One of skill in the art would have been motivated to use black pepper plant for extraction because it is known that extraction of black pepper plant provides for a higher amount of BCP than cannabis plant which is used for extraction in the method of US 2020/0199055 (Jansen et al). Thus, the claimed invention as a whole was clearly prima facie obvious, especially in the absence of evidence to the contrary. The claimed subject matter fails to patentably distinguish over the state art as represented be the cited references. Therefore, the claims are properly rejected under 35 USC § 103. Claims 1-9 are rejected under 35 U.S.C. 103 as being unpatentable over US 2020/0199055 (Jansen et al) and Geddo et al (Nutrients, 2019, 11, article 2788, pages 1-14) as applied to claims 1-5 and 7-9 above, and further in view of US 9,744,200 (Tucker et al). The cited references US 2020/0199055 (Jansen et al) and Geddo et al as above. The cited US 2020/0199055 (Jansen et al) is silent about the use of supercritical carbon dioxide for exacting terpenes from plant materials. However, the cited US 9,744,200 (Tucker et al) teaches the use of supercritical carbon dioxide for exacting terpenes and/or providing a terpene oil from plant materials (see abstract, see fig 1). The terpenes include beta-caryophyllene and others (col. 4, lines 43-46); the concertation of terpenes in terpene oil extracted by supercritical carbon dioxide can be 99% (col. 4, line 55); the terpene oil is further blended with cannabinoids extracted from plant materials (fig. 1) at any ratio (col. 2, lines 23-24), thereby, modifying contents of terpenes including BCP in the final plant cannabinoid extract. Therefore, it would have been obvious to one having ordinary skill in the art at the time the claimed invention was filed to extract terpenes from plant materials by using supercritical carbon dioxide and further to adjust or to modify ratios of extracted fractions to optimize amounts of terpenes including BCP in the final products depending on a desired goal. Thus, the claimed invention as a whole was clearly prima facie obvious, especially in the absence of evidence to the contrary. The claimed subject matter fails to patentably distinguish over the state art as represented be the cited references. Therefore, the claims are properly rejected under 35 USC § 103. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA AFREMOVA whose telephone number is (571)272-0914. The examiner can normally be reached Monday-Friday: 8.30am-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached at (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Vera Afremova October 27, 2026 /VERA AFREMOVA/ Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Sep 23, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788043
FOOD ADDITIVE FOR DISPERSING GANODERMA LUCIDUM POWDER AND METHOD FOR RAPIDLY DISPERSING GANODERMA LUCIDUM POWDER
2y 5m to grant Granted Nov 10, 2026
Patent 12779001
APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF DRUGS FOR TREATING NEURITIS
2y 5m to grant Granted Nov 03, 2026
Patent 12766172
COMPOSITION FOR PREVENTING, TREATING, OR IMPROVING GASTROINTESTINAL DISEASES COMPRISING STRAIN OF GENUS CORYNEBACTERIUM AND CULTURE THEREOF
4y 10m to grant Granted Oct 20, 2026
Patent 12747444
Heterotrophic Production Methods for Microbial Biomass and Bioproducts
5y 6m to grant Granted Sep 29, 2026
Patent 12721871
PROBIOTICS FOR THE PREVENTION OR TREATMENT OF VIRAL RESPIRATORY INFECTIONS
1y 10m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
51%
Grant Probability
80%
With Interview (+29.4%)
Low
PTA Risk
Based on 888 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month